BoomRay and Novartis Pharma sign $900m deal for radioligand therapy Pharmaceutical Business Review 10:45 Wed, 23 Sep
Novartis locks in preclinical Rlt under $900M Boomray deal BioWorld 18:34 Tue, 22 Sep Article paywall
BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset PR Newswire (Press Release) 05:04 Tue, 22 Sep
BoomRay and Novartis Pharma sign $900m deal for radioligand therapy Pharmaceutical Business Review 10:45 Wed, 23 Sep BoomRay Pharma Biotechnology
Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates The Korea Times 1d Consumer Electronics AstraZeneca Teva
Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica PMLiVE 13:14 Mon, 21 Sep Cosentyx Pharma CHMP
Novartis halts experimental ALS drug trial but acquires brain delivery platform Benzinga 17:49 Thu, 17 Sep VHB937 Article paywall
Lancet publishes full petrelintide trial: About 10% weight loss, Nausea in 20% as amylin drug enters Phase 3 Medical Daily 13h Diabetes Diet and Fitness Pharma
China exerting dominance in early stage clinical trials BioWorld 11h China Pharma China Politics Article paywall
Bespak expands next-gen nasal offering with launch of NasaDose European Pharmaceutical Manufacturer 18h
Sanofi and Regeneron expand immunology partnership to the tune of $8bn Pharmaceutical Technology 20h Sanofi Regeneron Biotech
Regeneron, Sanofi Extend Dupixent Playbook With Four Next-Gen Immunology Antibodies Scrip Pharma Intelligence 1d Sanofi Regeneron Biotech
